GlassScriptPhysician profile
Lisa Sandrik
NPI 1255981668
$2,412.96
in general payments reported to CMS, 2019-2025
25 companies · $407 in 2025
The $407 reported for 2025 was more than what a typical Acute Care (Nurse Practitioner) provider received nationally (typical 2025 total: $151).
See the full distribution for Acute Care (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $52.55 · 2023: $1,203 · 2024: $751 · 2025: $407.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,360.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,360.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $436.45 | 2023-2025 | Jardiance |
| Amgen INC. | $348.97 | 2023-2025 | Repatha |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $241.18 | 2023-2025 | Lifevest |
| Novartis Pharmaceuticals Corporation | $228.89 | 2023-2025 | |
| Janssen Pharmaceuticals, INC | $187.20 | 2023-2024 | Xarelto |
| Merck Sharp & Dohme LLC | $144.82 | 2023-2025 | Verquvo |
| Astrazeneca Pharmaceuticals LP | $107.50 | 2023-2025 | Wainua |
| Actelion Pharmaceuticals US, INC. | $80.70 | 2023 | Uptravi, Opsumit |
| Bayer Healthcare Pharmaceuticals INC. | $58.67 | 2023-2025 | |
| Esperion Therapeutics, INC. | $57.94 | 2025 | Nexletol |
| Kiniksa Pharmaceuticals, LTD. | $56.63 | 2023 | Arcalyst |
| Boston Scientific Corporation | $53.82 | 2023-2024 | Lux-Dx Insertable Cardiac Monitor |
| Gilead Sciences, INC. | $52.55 | 2022 | |
| Sanofi-Aventis U.S. LLC | $49.87 | 2023 | |
| Edwards Lifesciences Corporation | $44.77 | 2023-2025 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $42.91 | 2024 | Ozempic, Rybelsus |
| Daiichi Sankyo INC. | $38.98 | 2023 | Injectafer |
| Pfizer INC. | $34.23 | 2023 | |
| Regeneron Healthcare Solutions, INC. | $31.00 | 2023 | Dupixent |
| E.R. Squibb & Sons, L.L.C. | $24.39 | 2024 | Camzyos |
| Scpharmaceuticals INC. | $21.60 | 2025 | |
| Lilly USA, LLC | $21.25 | 2025 | Zepbound, Mounjaro |
| Kiniksa Pharmaceuticals International, Plc | $20.25 | 2024 | Arcalyst |
| Heartflow, INC. | $14.36 | 2023 | Ffrct |
| Alnylam Pharmaceuticals INC. | $14.03 | 2023 | Amvuttra |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lisa Sandrik listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.